

0074491401



MATERIAL SAFETY DATA SHEET

Product Name: Magnesium Sulfate Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name And Address Hospira, Inc.
275 North Field Drive
Lake Forest, Illinois 60045
USA

Emergency Telephone CHEMTREC: 800 424-9300
Hospira, Inc. 224 212-2055

Product Name Magnesium Sulfate Injection, USP; Magnesium Sulfate In 5% Dextrose Injection; Magnesium Sulfate Solution

Synonyms None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Magnesium Sulfate Heptahydrate
Chemical Formula MgO₄S

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Magnesium Sulfate	33	7487-88-9	OM4508000
Water	67	7732-18-5	ZC0110000

3. HAZARD INFORMATION

Emergency Overview In clinical use, this material is used as an anticonvulsant. It may cause a laxative effect on the gastrointestinal tract if ingested. Possible target organs include the gastrointestinal tract, nervous system, cardiovascular system and heart.

Occupational Exposure Potential Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms No signs or symptoms from occupational exposure are known. Clinical data suggest the following: vomiting, diarrhea, abdominal pain, and electrolytes imbalances.

Medical Conditions Aggravated by Exposure Hypersensitivity to the material and/or similar materials. Pre-existing ailments in the following organs: nervous system, gastrointestinal system, cardiovascular system.

Product Name: Magnesium Sulfate Injection, USP

4. FIRST AID MEASURES

Eye Contact:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin Contact:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.
Ingestion:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability:	Non-flammable.
Fire & Explosion Hazard:	None
Extinguishing Media:	Use extinguishing media appropriate for primary cause of fire.
Special Fire Fighting Procedures	No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal	Absorb with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.
-----------------------------------	---

7. HANDLING AND STORAGE

Handling	No special handling required.
Storage	No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F).
Special Precautions	Protect from freezing and extreme heat.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Exposure limits		
	OSHA-PEL	ACGIH-TLV	Hospira EEL
Magnesium Sulfate	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: Not Established STEL: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration -- Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists -- Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

Product Name: Magnesium Sulfate Injection, USP

Respiratory Protection	Respiratory protection is not needed during normal product use.
Skin Protection	If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.
Eye Protection	Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.
Engineering Controls	Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Clear solution
Odor	Odorless
Boiling Point	Not Determined
Freezing Point	Not Determined
Vapor Pressure	Not Determined
Vapor Density (Air=1)	Not Applicable
Evaporation Rate	Not Determined
Bulk Density	Not Determined
Specific Gravity	Not Determined
Solubility	Water
pH	3.5- 7.0

10. STABILITY AND REACTIVITY

Chemical Stability	Stable under standard use and storage conditions.
Incompatibilities	Not Determined
Hazardous Decomposition Products	Toxic fumes of sulfur oxides
Hazardous Polymerization	Not Determined.

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity - Oral:

Ingredient(s)	Percent	Test Type	Value	Units	Species
Magnesium Sulfate	100	LD50	5000	mg/kg	Mice
			3000		Rabbits

LD50 is the dosage producing 50% mortality.
Product contains approximately 33% Magnesium Sulfate.

Mutagenicity	Not Determined
Target Organ Effects	In clinical use target organ effects include the gastrointestinal tract, nervous system, cardiovascular system.

Product Name: Magnesium Sulfate Injection, USP

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity Not Available

13. DISPOSAL CONSIDERATIONS:

Waste Disposal Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status Not Regulated

CERCLA Status Not Regulated

SARA Status Not Regulated

RCRA Status Not Regulated

PROP 65 (Calif.) Not Regulated

Notes: TSCA Toxic Substance Control Act
 CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
 SARA Superfund Amendments and Reauthorization Act
 RCRA US EPA, Resource Conservation and Recovery Act
 Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator Global Occupational Toxicology

Date Prepared September 15, 2005

Date Revised October 21, 2008

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.